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Abstract
OBJECTIVE: To evaluate systematically the efficacy
and safety of Danshenchuanxiongqin Injection
(DCI) in the treatment of unstable angina pectoris
(UAP).
METHODS: Randomized controlled trials (RCTs) re-
garding DCI used for treating UAP were searched in
English and Chinese electronic databases from in-
ception to January 2014. Two reviewers indepen-
dently retrieved RCTs and extracted relevant infor-
mation. The Cochrane risk of bias method was used
to assess the quality of included studies, and a Me-
ta-analysis was conducted with Review Manager
5.2 software.
RESULTS: Eleven RCTs involving 1034 participants
were included. The methodological quality was rel-
atively passable. The Meta-analysis indicated that
the combined use of DCI and conventional treat-
ment with Western Medicine (WM) was more effica-
cious in the outcomes of total effective rate [Rela-
tive Risk (RR) = 1.27, 95% CI (confidence interval;
1.18, 1.35), P < 0.000 01], the total effective rate of
ECG [RR = 1.40, 95% CI (1.18, 1.66), P < 0.000 01], to-
tal cholesterol [Mean difference (MD) =－0.58, 95%
CI (－0.83,－0.33), P < 0.000 01], total triglycerides
[MD =－0.36, 95% CI (－0.54,－0.17), P = 0.0001],
and the number of ST-segment depression [MD =
－0.36, 95% CI (－0.54, －0.17), P = 0.0001]. There
were two adverse drug reactions reported in one
study.
CONCLUSION: Based on the systematic review, DCI
combined with WM appeared to be efficacious in
the treatment UAP. However, the evidence of DCI
for treating UAP requires large-scale and dou-
ble-blind RCTs to substantiate these findings.
© 2016 JTCM. All rights reserved.
Key words: Danshenchuanxiongqin injection; An-
gina, unstable; Review; Meta-analysis
INTRODUCTION
Unstable angina pectoris (UAP) is a series of clinical
syndromes, which belongs to ischemic cardiovascular
and cerebrovascular diseases.1 It has the characteristics
with severe chest pain, long duration, poor efficacy of
nitrates, and easily deteriorating into AMI or sudden
death.2 Therefore, UAP has been one of research hot-
spots in recent years.
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Modern medical research has shown that the pathologi-
cal basis of UAP is local coronary artery with ischemic
lesion,3 which is mainly related to vascular endothelial
injury, platelet activation barriers, inflammation re-
sponse, vasospasm, thrombosis formation and other rel-
evant factors.4,5 Currently, the conventional therapy
with Western Medicine (WM) includes anti-ischemia,
anti-thrombosis, thrombolysis and lipid-lowering, how-
ever, the treated patients may have headaches, heart pal-
pitations, or other side effects that caused by the over-
dose.6-8 In view of this, to explore an efficacious, safe,
convenient and economical treatment measure is very
important.
In Traditional Chinese Medicine, UAP can be treated
by invigorating Qi and promoting blood circulation. 9
Danshenchuanxiongqin injection (DCI) is a phyto-
chemical drug that synthesized by Ligustrazine Hydro-
chloride (chemical name: 2,3,5,6 - tetramethyl pyr-
azine hydrochloride), which is extracted from Chuanx-
iong (Rhizoma Chuanxiong), and tanshinol [chemical
name: β-(3, 4- dihydroxyphenyl) lactic acid], which is
extracted Danshen (Radix Salviae Miltiorrhiae). Mod-
ern research has shown that tanshinol can increase coro-
nary blood flow, improve microcirculation, promote
open collateral circulation, reduce extent of myocardial
ischemia, and protect the ischemic myocardium. At
the same time, it can improve blood rheology index, in-
crease the hypoxia tolerance, anti-peroxidation of lipid,
reduce free radicals, and so on. Ligustrazine is a new
calcium antagonist, which can inhibit the production
of free radical, improve the activity of endogenous su-
peroxide dismutase, inhibit platelet aggregation and fi-
brosis, and regulate the lipid Metabolism.10-12 The two
active ingredients are combined to have strong efficacy
on dilating coronary arteries, reducing blood viscosity,
improving hemodynamics and microcirculation, regu-
lating the platelet function and anticoagulation.13
There was one systematic review14 regarding DCI in
the treatment of angina pectoris, but it may lack some
preciseness that drugs used in control groups had big
difference. Therefore, it is necessary to assess the cur-
rent trials to systematically review the potential effect
and safety for the use of DCI in the treatment of UAP.
MATERIALS ANDMETHODS
This study was conducted according to the Cochrane
practice, including pre-specified objectives, search strat-
egy, inclusion and exclusion criteria, quality assess-
ment, data collection and Meta-analysis.
Study search
Randomized controlled trials (RCTs) were respectively
retrieved by searching the following databases from Jan-
uary 1979 to January 2014: China National Knowl-
edge Infrastructure (CNKI), Wanfang Database, China
Science and Technology Journal Database (VIP), Chi-
nese Biomedical Literature Database (CBM), PubMed,
and Cochrane Library. No limit placed on published
language.
Different search strategies were combined as follows:
for English databases, such as PubMed, the search
terms included ("Danshenchuanxiongqin" [Full text]
OR "danshen chuanxiongzine" [Full text] OR "dansh-
enchuanxiongqin" [Full text] OR "danshenchuanxiong-
zine" [Full text] OR "salviae miltiorrhizae and ligustra-
zine" [Full text]) AND ("Unstable angina pectoris"
[MeSH terms] OR "angina" [MeSH terms] OR "pecto-
ris" [MeSH terms] OR "preinfarction angina" [MeSH
terms] OR "preinfarction anginas"); for Chinese data-
bases, such as CNKI, the search terms included ("Dan-
shenchuanxiongqin" [MeSH terms]) AND "Bu Wen
Ding Xin Jiao Tong" [MeSH terms] OR "Bu Wen
Ding Xing Xin Jiao Tong" [MeSH terms]).
Inclusion criteria
Studies met the following criteria were included. RCTs
regarding DCI in the treatment of UAP were included,
regardless of blinding. The diagnostic criterion of UAP
was determined by Branch of Chinese Medical Society
of Cardiology in 2000, which including the frequency
of chest pain paroxysm, the duration, the activity
thresholds induced angina, and the abnormal ST-seg-
ment of ECG. 15 No limit was placed on patients' age,
gender, and races. The experiment group and control
group were both given the WM therapy, such as an-
ti-ischemia, anti-thrombosis, thrombolysis and lip-
id-lowering. Based on the treatment that used in the
control group, DCI was given to the experiment
group. The efficacy criterion was "clinical guidelines
for cardiovascular system drugs", which was deter-
mined by Ministry of Health Pharmaceutical Council
in 1993.16 The primary outcomes were the total clinical
effective rate and the total effective rate of electrocar-
diogram (ECG). The total effective rate = (number of
patients of significantly effective + number of patients
of effective) / total number × 100 %. Significantly ef-
fective was determined when the same degree of exer-
tion did not cause UAP, at least reduce over 80%, or
the improvement of angina degree is over gradeⅡ. Ef-
fective was determined by the number of angina epi-
sode decreased by 50%-80% , or the improvement of
angina degree in grade Ⅰ-Ⅱ. Invalid was determined
that the number of angina episode decreased within
50% , or the improvement of angina degree within
grade Ⅰ, even no improvement. The total effective
rate of ECG = (number of patients of significantly ef-
fective + number of patients of effective) / total num-
ber × 100% . Significantly effective was determined
when ECG moves down, and the recovery of ST-seg-
ment is over 0.1mV or return to normal at resting. Ef-
fective was determined when the recovery of ST-seg-
ment is in 0.05-0.1 mV or the inverted T-wave is light-
er than 50%. Invalid was determined when ECG is the
same as that before treatment at resting. Secondary out-
comes were hemorheology indicators, such as total cho-
145
JTCM |www. journaltcm. com April 15, 2016 |Volume 36 | Issue 2 |
Zhang XM et al. / Systematic Review
lesterol, total triglyceride; the number of ST-segment
depression, and the number of adverse drug reactions
(ADRs) / adverse drug events (ADEs).
Exclusion criteria
We excluded the studies with the patients of active
bleeding or internal bleeding history, acute myocardial
infarction, severe hypertension, severe liver and kidney
dysfunction, and any Chinese herbal medicine was
combined use in both groups.
Date extraction and quality assessment
For the included studies, two reviewers extracted the
data, and screened them according to the inclusion cri-
teria. Any disagreements on data extraction and study
evaluation were resolved through discussion. The ex-
tracted data included study type, patients' characteris-
tics, and the information about treatment. We strictly
assessed the risk of bias of the included trials according
to the Cochrane risk of bias tool.17 This assessed ran-
dom sequence generation, allocation concealment,
blinding of participants and personnel, blinding of out-
come assessment, incomplete outcome data, selective
reporting, and other bias. For each item, there were
three alternative grades of risk: low risk of bias, unclear,
and high risk of bias. When inadequate information
was presented in the article or we were unable to explic-
itly judge "high" or "low", the item was judged as "un-
clear". Two researchers independently completed and
mutually checked the allocated grades. Any dispute
solved through discussion or with the assistance of a
third researcher.
Statistical analysis
Revman 5.2 software package that produced and updat-
ed by the Nordic Cochrane Centre was used to ana-
lyze the collected data. Relative risk (RR) was used
for dichotomous data, and mean difference (MD)
was used for continuous variables, both with 95%
confidence interval (95% CI); P < 0.05 was consid-
ered statistically significant between experimental and
control group. The Chi-square test was used for
checking the heterogeneity between studies, and I 2
was used to show the size of heterogeneity. If P >
0.1 and I 2 < 50%,18 there was determined to be little
heterogeneity between studies, then we used a fixed
effect model, otherwise we should use a random ef-
fect model. If the number of included trials was suffi-
cient, a funnel plot would be carried out to assess
publication bias. Sensitivity analysis was performed
on to inspect the stability of the result.
RESULTS
Search result
In this review, 67 articles were retrieved from the data-
bases listed above. After excluding duplications, re-
views and obviously irrelevant studies by reading the ti-
tles and abstracts, 37 papers were downloaded for fur-
ther assessment. After reading full texts, studies that
did not meet the inclusion criteria, non-RCTs, or indi-
vidual clinical cases were excluded. A total of 11 stud-
ies were included,11,16,19-27 as shown in Figure 1.
Figure 1 Flow chart of literature search
CNKI: China National Knowledge Infrastructure Database; CBM: Chinese Biomedical Literature Database; VIP: China Science and
Technology Journal Database; RCTs: randomized controlled trials.
Studies that retrieved through databases (n =
67): CNKI (n = 31), Wan fang (n = 4), VIP (n =
4), CBM (n = 26), PubMed (n = 0), Cochrane
Library (n = 1)
Studies obtained through
other resources (n = 0)
Total (n = 67)
Excluding duplication
(n = 30)
Full text (n = 37)
Excluding cases (n = 1),
and studies not meeting the
inclusion criteria (n = 25)
RCTs meeting inclusion
criteria (n = 11)
RCTs included in the
Meta-analysis (n = 11)
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Studies description
Eleven included studies, which involved in 1034 partic-
ipants, were all published in Chinese journal literature
databases from 2008 to 2013. There were 544 partici-
pants in experiment group, while 490 in control
group. The average age of the patients was approxi-
mately 62.2, and all trials included more males
(64.0%) than females. All the interventions in experi-
ment groups were DCI combined with WM that the
same as control group, which were primarily nitrate, as-
pirin, statins, low molecular weight heparin, β-block-
ers, and so on. DCI was from Beit Pharmaceuticals
Ltd. in Guizhou, and its dosage was almost 10 mL ev-
ery day. The duration of both experimental and con-
trol group was about 2 weeks. More details regarding
the individual trials were presented in Table 1.
Quality of the included studies
The included studies quality was evaluated by Co-
chrane risk of bias tool. There were 3 studies16,20,23 de-
scribed the method that used to generate the allocation
sequence, one of which was based on the order of ad-
mission, and the other two were based on the random
digits table, while others only mentioned "random".
And all the studies did not refer blinding. Therefore,
the quality of the included studies was relatively pass-
able, and more details of the trials were presented in
Figure 2.
Total clinical effective rate
There were 9 studies11,16,19-23,26 compared the total clini-
cal effective rate. After the test for heterogeneity (P =
0.50 > 0.1, I ² = 0 < 50%), we can use a fixed-effects
model. The Meta-analysis showed that the clinical effi-
cacy of DCI combined with WM was better than con-
trol group, the statistical difference between the two
groups was significant [RR = 1.27, 95% CI (1.18,
1.35), P < 0.000 01] (Figure 3).
Sensitivity analysis
To confirm the stability of the result of the total clini-
cal effective rate, we respectively removed the most and
the least weighted, and changed from fixed mode to
random mode. After removing the most weighted
(Lang et al 23) was RR = 1.29 [95% CI (1.19, 1.40)].
The result of removing the least (Zhao et al 20) was
RR = 1.27 [95% CI (1.18, 1.36)]. The result of chang-
ing the mode was RR = 1.22 [95% CI (1.15, 1.30)].
Comparing with the previous results, only the result of
changing analysis mode appeared slight differences, the
other two were no obviously diversity, and there was
not any outlier, so the degree of the sensitivity of the
study was not high.
Publication bias
We assessed publication bias of the total effective rate
with the funnel plot. The result of the figure showed
that therewas publication bias in the analysis (Figure 4).
Total effective rate of ECG
There were 4 studies11,16,20,26 compared the total effective
rate of ECG. After the test for heterogeneity (P =
0.74 > 0.1, I ² = 0 < 50%), we used a fixed-effects mod-
el. The Meta-analysis showed that the therapy of DCI
combined WM was more effective, the statistical differ-
ence between the two groups was significant [RR =
1.40, 95% CI (1.18, 1.66), P < 0.000 01] (Figure 5).
Total cholesterol (TC)
There were 4 studies 22-25 mentioned TC. After the test
for heterogeneity (P < 0.000 01, I ² = 89% > 25%), we
should use a random model. The result showed that
the effect of experiment group was better than the con-
trol group in decreasing TC. The statistical difference
between the two groups was significant [MD =－0.58,
95% CI (－0.83,－0.33), P < 0.000 01].
Total triglycerides (TG)
There were 4 studies22-25 mentioned TG. After the test
for heterogeneity (P < 0.000 01, I ² = 86% > 50%), we
should use a random model. The result showed that
the therapy of DCI combined WM was more effective
in decreasing TG. The statistical difference between
the two groups was significant [MD =－0.36, 95% CI
(－0.54,－0.17), P = 0.0001].
Number of ST-segment depression
There were 3 studies11,22,27 mentioned the number of
ST-segment abnormality that appears. After the test for
heterogeneity (P = 0.15, I² = 46% < 50%), we may use
a fixed model. The result showed that the effect of ex-
periment group was better than the control group in
decreasing the number of ST-segment abnormality that
appears. The statistical difference between the two
groups was significant [MD = － 1.12, 95% CI (－
1.45,－0.80), P < 0.000 01].
Safety
Only 1 study16 reported 2 ADRs in the experiment
group, which presented mild rash, and disappeared by
slowing down the speed of infusion and using anti-al-
lergic drugs. There were 6 studies11,20,21,24-26 put forward
clearly no ADR in their studies, and the other 4 studies
19,22,23,27 did not pay attention to that. Accordingly, we
could not conclude that DCI was absolutely safe.
DISCUSSION
Following the literature analysis, we concluded that
based on WM, DCI can significantly improve the treat-
ment effect of UAP, which represented in increasing
the total clinical effective rate and the total effective
rate of ECG, improving the blood flow rheology index,
especially reflected in the total cholesterol and total tri-
glyceride, and reducing the number of ST-segment de-
pression.
In the Meta-analysis, we discussed the outcomes in-
cluding the total clinical effective rate, the total effec-
tive rate of ECG, total cholesterol, total triglyceride,
and the number of ST-segment depression. The total
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clinical effective rate and
the total effective rate of
ECG reflected the efficacy
of DCI for treating UAP
from the overall. The path-
ological basis of UAP is ath-
erosclerosis, which is associ-
ated with lipid level.28 Total
cholesterol and triglycer-
ides can well represent the
changes in lipid level, there-
fore, total cholesterol and
total triglyceride should be
important indicators for
evaluate the efficacy of
DCI in the tre- atment of
UAP. In addition, blood
rheology level and inflam-
mation response are also
important factors to cause
the instability of plaque.24
However, few of the includ-
ed studies compared the bl-
ood viscosity coefficient,
sCD40L, CRP and other
inflammatory factors.
From the results of the Me-
ta-analysis and the statistics
in clinical, we could find
ADRs of DCI mainly occa-
sionally presented rash.29
However, because Chinese
herbal injections have the
characters of multi-compo-
nent and multi-target,
widely different among pa-
tients, and many other in-
fluence factors, we should
not ignore other ADRs
that may be seen in clini-
cal. For example, Song et al
30 reported 1 case that DCI
led to shock and low blood
sugar, which may be related
to Danshen (Radix Salviae
Miltiorrhiae) that it can de-
crease the blood sugar and
catecholamines (CA). CA
can promote the glycogen
gluconeogenesis by elevat-
ing the level of cAMP,
which can cause a moderat-
ing effect on glucose Me-
tabolism in the end. There-
fore, the medical staffs
should observe the changes
of patient's condition when
applied DCI. Another ex-Stu
dy
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ample is Feng et al 31 reported 18 patients presented
chills, fever, headache, accompanied by shortness of
breath, cyanosis, blood pressure and other symptoms
when injected DCI. And they found that the severity
of symptoms of ADRs and age was positively correlat-
ed. Accordingly, special attention should be given to
the elderly patients in clinical. In addition, DCI was
not suitable to coexist with furosemide, 32 there were
varying degrees of turbidity when they two mixed, re-
gardless the drug concentration, which should pay
more attention in clinical.
In the systematic review, there were some limitations,
which mainly included the following aspects. (a) The
quality of the included RCTs was just passable, and
lack large-scale RCTs. 8 of 11 studies marked "ran-
dom" only, but did not describe specific random alloca-
Figure 2 Summary of risk of bias of included trials
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Cai2011 21
He2009 19
Huang2008 16
Lang2012 23
Li2013 26
Ren2012 25
Wang2011 28
Xue2012 24
Zhang2010 11
Zhang2013 27
Zhao2010 20
Figure 3 Meta-analysis of the total clinical effective rate of using DCI plusWM vsWM for UAP
DCI: Danshenchuanxiongqin Injection;WM:Western Medicine; UAP: unstable angina pectoris.
Figure 4 Funnel plot of the included trials in total clinical ef-
fective rate
0
0.05
0.1
0.15
0.20.2 0.5 1 2 5
RR
SE (log［RR］)
Figure 5 Meta-analysis of the total effective rate of ECG of using DCI plusWM vsWM for UAP
DCI: Danshenchuanxiongqin injection;WM:Western Medicine; UAP: unstable angina pectoris; ECG: electrocardiogram.
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tion method, and none of the articles mentioned blind-
ing. (b) All trials were published in Chinese, but lack
of RCTs in other languages, which may be related to
DCI only to be used in China, so we could not exclude
potential publication bias. Therefore, more studies
with rigorously designed RCTs are needed to further
improvement.
In conclusion, combined with all discussed above, the
results of the Meta-analysis illustrated that the com-
bined use of DCI and WM was more efficacious in the
outcomes of the total clinical effective rate, the total ef-
fective rate of ECG, total cholesterol, total triglycer-
ides, and the number of ST-segment depression. In
summary, DCI in the treatment of UAP has many sig-
nificant advantages, stability efficacy, but the safety of
DCI that we could not have a clear conclusion on,
which needmedical staffs paymore attentionwhenused.
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